At what stage is this treatment used?
- First-line combination and second-line monotherapy treatment of metastatic bowel cancer.
Is Camptosar available on the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Camptosar is PBS-subsidised as a treatment option for patients with metastatic bowel cancer. Note: In first-line usage, effectiveness and tolerance may be improved when Irinotecan is combined with an infusional 5-fluorouracil regimen (e.g. FOLFIRI).
Download the Consumer Medicine Information (CMI) for Camptosar.
